Learning the lessons (again) of the challenges of conducting sham-controlled device trials in hypertension

EuroIntervention 2023;19:541-543. DOI: 10.4244/EIJ-E-23-00036

Andrew S.P. Sharp
Andrew S.P. Sharp1, MD; Ajay J. Kirtane2, MD, SM
1. University Hospital of Wales and Cardiff University, Cardiff, UK; 2. NewYork-Presbyterian/Columbia University Irving Medical Centre, New York, NY, USA
More people in Europe are likely to have died from hypertension-associated cardiovascular disease during the COVID-19 pandemic than from COVID-19 itself12. As we look back at a pandemic that caused so much harm – economic, social, and health-related – readers would be forgiven for not noticing that for decades we have been living through a slow-motion global epidemic of hypertension that shows no signs of abating.

The leading cause of premature death in the world is hypertension, which begs the question “how well are we doing at treating it?” Not very well is the answer. In the ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
EAPCI Focus on the EAPCI Online & Communication Committee

Latest news